Experimental evidence suggests exenatide, a glucagon-like peptide 1 receptor analogue, has
significant cardiovascular protective effects in various conditions. The investigators
examined whether conventional use of exenatide at the time of primary percutaneous coronary
intervention would reduce the infarct size in patients with ST-segment elevation myocardial
infarction (STEMI).